Association of Ki-67 With Clinicopathological Factors in Breast Cancer

被引:1
|
作者
Nishit [1 ]
Nigam, Jitendra S. [1 ]
Kumar, Tarun [1 ]
Bharti, Shreekant [1 ]
Surabhi [1 ]
Sinha, Ruchi [1 ]
Bhadani, Punam P. [1 ]
机构
[1] All India Inst Med Sci, Pathol Lab Med, Patna, India
关键词
diagnosis; estrogen recepter; progestron recepter; her2neu; breast cancer; prognosis; INDEX; EXPRESSION; CARCINOMA; BIOMARKER;
D O I
10.7759/cureus.15621
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Carcinoma of the breast is one of the most common cancer in females, with preponderance among urban females. The patient's age, tumor size, lymph node status, histological type, histological grade, lymphovascular invasion, hormonal receptor status, human epidermal growth factor receptor 2 (Her2neu) expression, and Ki-67 labeling index for proliferation rate can help determine the appropriate management strategy in these patients. The authors conducted this descriptive retrospective study to assess the association of Ki-67 with clinicopathological parameters in a newly established institute. This may help guide treatment planning in developing countries. Methodology Patients diagnosed with primary breast cancer in our institute between January 2017 and March 2020 were included in this study. The clinicopathological prognostic factors were retrieved from the records. Results A total of 129 cases of core needle biopsy and mastectomy specimens were included in this study. The patient's mean age and median age were 47.41 and 47 years, respectively. Only 56 specimens of mastectomy were received. T2 (26/56) was the most common tumor size. Grading was done in 46 cases, and grade 2 (23/46) was the most common. Estrogen, progesterone, and Her2neu were positive in 65, 61, and 59 cases, respectively. Only estrogen receptor (ER) expression (p = 0.035) and Her2neu (p = 0.035) overexpression were significantly correlated with Ki-67. Conclusions Ki-67 expression was correlated with clinicopathological factors. Only ER expression and Her2neu overexpression were significantly associated with Ki-67. Hence, patients with high Ki-67 expression may have better responses to hormonal therapy and chemotherapy.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer
    Inari, Hitoshi
    Suganuma, Nobuyasu
    Kawachi, Kae
    Yoshida, Tatsuya
    Yamanaka, Takashi
    Nakamura, Yoshiyasu
    Yoshihara, Mitsuyo
    Nakayama, Hirotaka
    Masudo, Katsuhiko
    Oshima, Takashi
    Yokose, Tomoyuki
    Rino, Yasushi
    Shimizu, Satoru
    Miyagi, Yohei
    Masuda, Munetaka
    [J]. BREAST CANCER, 2017, 24 (06) : 748 - 755
  • [42] Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer
    Heusinger, Katharina
    Jud, Sebastian M.
    Haeberle, Lothar
    Hack, Carolin C.
    Fasching, Peter A.
    Meier-Meitinger, Martina
    Lux, Michael P.
    Hagenbeck, Carsten
    Loehberg, Christian R.
    Wittenberg, Thomas
    Rauh, Claudia
    Wagner, Florian
    Uder, Michael
    Hartmann, Arndt
    Schulz-Wendtland, Ruediger
    Beckmann, Matthias W.
    Wachter, David L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (03) : 885 - 892
  • [43] Inter-observer concordance of Ki-67 labeling index in breast cancer: Japan Breast Cancer Research Group (JBCRG) Ki-67 Ring Study
    Ueno, T.
    Mikami, Y.
    Yoshimura, K.
    Tsuda, H.
    Kurosumi, M.
    Masuda, S.
    Horii, R.
    Toi, M.
    Sasano, H.
    [J]. CANCER RESEARCH, 2012, 72
  • [44] Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer
    Hitoshi Inari
    Nobuyasu Suganuma
    Kae Kawachi
    Tatsuya Yoshida
    Takashi Yamanaka
    Yoshiyasu Nakamura
    Mitsuyo Yoshihara
    Hirotaka Nakayama
    Katsuhiko Masudo
    Takashi Oshima
    Tomoyuki Yokose
    Yasushi Rino
    Satoru Shimizu
    Yohei Miyagi
    Munetaka Masuda
    [J]. Breast Cancer, 2017, 24 : 748 - 755
  • [45] Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
    Choi, Soon Bo
    Park, Jung Min
    Ahn, Jee Hyun
    Go, Jieon
    Kim, Jeeye
    Park, Hyung Seok
    Kim, Seung Il
    Park, Byeong-Woo
    Park, Seho
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (02) : 343 - 352
  • [46] Proliferative activity in human breast cancer: assessment of Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
    Bragantini, E.
    Fasanella, S.
    Eccher, C.
    Leonardi, E.
    Aldovini, D.
    Morelli, L.
    Ferro, A.
    Cuorvo, L. V.
    Dalla Palma, P.
    Barbareschi, M.
    [J]. VIRCHOWS ARCHIV, 2010, 457 (02) : 168 - 168
  • [47] A Machine Learning Approach for the Association of ki-67 Scoring with Prognostic Factors
    Dirican, E.
    Kilic, E.
    [J]. JOURNAL OF ONCOLOGY, 2018, 2018
  • [48] Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
    Soon Bo Choi
    Jung Min Park
    Jee Hyun Ahn
    Jieon Go
    Jeeye Kim
    Hyung Seok Park
    Seung Il Kim
    Byeong-Woo Park
    Seho Park
    [J]. Breast Cancer Research and Treatment, 2022, 192 : 343 - 352
  • [49] The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients
    Madani, Seyed-Hamid
    Payandeh, Mehrdad
    Sadeghi, Masoud
    Motamed, Hajar
    Sadeghi, Edris
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2016, 37 (02) : 95 - 99
  • [50] Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors
    Kermani, Touraj Asvadi
    Kermani, Iraj Asvadi
    Faham, Zhaleh
    Dolatkhah, Roya
    [J]. BIOMEDICAL RESEARCH AND THERAPY, 2019, 6 (02): : 2986 - 2991